Nouveau Life Pharmaceuticals Stock Shares Owned By Institutions
| NOUV Stock | USD 0.0001 0.00 0.00% |
Fundamental analysis of Nouveau Life allows traders to better anticipate movements in Nouveau Life's stock price by examining its financial health and performance throughout various phases of its business cycle.
Nouveau |
Nouveau Life Pharmaceuticals Company Shares Owned By Institutions Analysis
Nouveau Life's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 0.0% of Nouveau Life Pharmaceuticals are shares owned by institutions. This is 100.0% lower than that of the Financial Services sector and about the same as Shell Companies (which currently averages 0.0) industry. The shares owned by institutions for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
| All Next | Launch Module |
Nouveau Fundamentals
| Return On Equity | -2.2 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | 722.68 K | |||
| Price To Earning | (0.01) X | |||
| Price To Book | 22.72 X | |||
| EBITDA | (163.87 K) | |||
| Net Income | (357.25 K) | |||
| Cash And Equivalents | 1.1 K | |||
| Cash Flow From Operations | (22.91 K) | |||
| Earnings Per Share | (0.02) X | |||
| Beta | -4.22 | |||
| Market Capitalization | 484.8 K | |||
| Total Asset | 1.33 M | |||
| Retained Earnings | (236 K) | |||
| Working Capital | (145 K) | |||
| Current Asset | 1 K | |||
| Current Liabilities | 146 K | |||
| Net Asset | 1.33 M |
About Nouveau Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nouveau Life Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nouveau Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nouveau Life Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nouveau Pink Sheet Analysis
When running Nouveau Life's price analysis, check to measure Nouveau Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nouveau Life is operating at the current time. Most of Nouveau Life's value examination focuses on studying past and present price action to predict the probability of Nouveau Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nouveau Life's price. Additionally, you may evaluate how the addition of Nouveau Life to your portfolios can decrease your overall portfolio volatility.